3-(4-Piperidinyl)-1H-indole → 2-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-nicotinic acid ethyl ester

HRID 457812

반응식

HRID 457812 반응식
[NH:1]1[CH2:6][CH2:5][CH:4]([C:7]2[C:15]3[C:10](=[CH:11][CH:12]=[CH:13][CH:14]=3)[NH:9][CH:8]=2)[CH2:3][CH2:2]1.[CH2:16]([O:18][C:19](=[O:28])[C:20]1[CH:25]=[CH:24][CH:23]=[N:22][C:21]=1[CH2:26]Br)[CH3:17]>>[CH2:16]([O:18][C:19](=[O:28])[C:20]1[CH:25]=[CH:24][CH:23]=[N:22][C:21]=1[CH2:26][N:1]1[CH2:6][CH2:5][CH:4]([C:7]2[C:15]3[C:10](=[CH:11][CH:12]=[CH:13][CH:14]=3)[NH:9][CH:8]=2)[CH2:3][CH2:2]1)[CH3:17]

참가 물질

3

실험 절차

This compound was prepared following the procedure described in example 1 (part D) starting with 0.5 g (2.5 mmol) of 3-piperidin-4-yl-1H-indole and 0.65 g (3.25 mmol) of 2-bromomethyl-nicotinic acid ethyl ester. After the standard purification, 0.84 g (92% of yield) of 2-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-nicotinic acid ethyl ester were obtained.

후처리

  1. customThis compound was prepared
  2. customAfter the standard purification

출처 및 근거

ORD 기록
ord-85e4af361a44410c8e77b8e15f557960
출처 데이터셋
uspto-grants-2007_03
특허 번호
US07189741B2

연결된 노트

불러오는 중…